Share

August 2019; 5 (4) ArticleOpen Access

Genetic risk of Parkinson disease and progression:

An analysis of 13 longitudinal cohorts

Hirotaka Iwaki, Cornelis Blauwendraat, Hampton L. Leonard, Ganqiang Liu, Jodi Maple-Grødem, Jean-Christophe Corvol, Lasse Pihlstrøm, Marlies van Nimwegen, Samantha J. Hutten, Khanh-Dung H. Nguyen, Jacqueline Rick, Shirley Eberly, Faraz Faghri, Peggy Auinger, Kirsten M. Scott, Ruwani Wijeyekoon, Vivianna M. Van Deerlin, Dena G. Hernandez, Aaron G. Day-Williams, Alexis Brice, Guido Alves, Alastair J. Noyce, Ole-Bjørn Tysnes, Jonathan R. Evans, David P. Breen, Karol Estrada, Claire E. Wegel, Fabrice Danjou, David K. Simon, Bernard Ravina, Mathias Toft, Peter Heutink, Bastiaan R. Bloem, Daniel Weintraub, Roger A. Barker, Caroline H. Williams-Gray, Bart P. van de Warrenburg, Jacobus J. Van Hilten, Clemens R. Scherzer, Andrew B. Singleton, Mike A. Nalls
First published July 9, 2019, DOI: https://doi.org/10.1212/NXG.0000000000000348
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
512

Share

This article has a correction. Please see:

Article Figures & Data

Figures

  • Figure 1
    Figure 1 Forest plots for GBA (p.N370S and p.T408M) variants and symptoms of Parkinson disease

    DATATOP = Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism; DIGPD = Drug Interaction with Genes in Parkinson's Disease; HBS = Harvard Biomarkers Study; NET-PD_LS1 = NIH Exploratory Trials in Parkinson's Disease Large Simple Study 1; Oslo = Oslo PD study; ParkFit = ParkFit study; ParkWest = the Norwegian ParkWest study; PDBP = Parkinson's Disease Biomarker Program; PICNICS = Parkinsonism: Incidence and Cognitive and Non-motor heterogeneity In CambridgeShire; PPMI = Parkinson's Progression Markers Initiative; PreCEPT/PostCEPT = Parkinson Research Examination of CEP-1347 Trial with a subsequent prospective study; ProPark = Profiling Parkinson's Disease study; Udall = Morris K. Udall Centers for Parkinson's Research. * Indicates Beta in a Cox model; ** indicates Beta in a logistic model at baseline.

  • Figure 2
    Figure 2 Forest plots for GBA (p.E365K) variants and symptoms of Parkinson disease

    DATATOP = Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism; DIGPD = Drug Interaction with Genes in Parkinson's Disease; HBS = Harvard Biomarkers Study; NET-PD_LS1 = NIH Exploratory Trials in Parkinson's Disease Large Simple Study 1; Oslo = Oslo PD study; ParkFit = ParkFit study; ParkWest = the Norwegian ParkWest study; PDBP = Parkinson's Disease Biomarker Program; PICNICS = Parkinsonism: Incidence and Cognitive and Non-motor heterogeneity In CambridgeShire; PPMI = Parkinson's Progression Markers Initiative; PreCEPT/PostCEPT = Parkinson Research Examination of CEP-1347 Trial with a subsequent prospective study; ProPark = Profiling Parkinson's Disease study; Udall = Morris K. Udall Centers for Parkinson's Research. * Indicates Beta in a Cox model; ** indicates Beta in a logistic model at baseline; *** indicates Beta in a linear mixed model.

  • Figure 3
    Figure 3 Forest plots for non-GBA risk variants/genetic risk score and symptoms or features of Parkinson disease

    DATATOP = Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism; DIGPD = Drug Interaction with Genes in Parkinson's Disease; HBS = Harvard Biomarkers Study; NET-PD_LS1 = NIH Exploratory Trials in Parkinson's Disease Large Simple Study 1; Oslo = oslo PD study; ParkFit = ParkFit study; ParkWest = the Norwegian ParkWest study; PDBP = Parkinson's Disease Biomarker Program; PICNICS = Parkinsonism: Incidence and Cognitive and Non-motor heterogeneity In CambridgeShire; PPMI = Parkinson's Progression Markers Initiative; PreCEPT/PostCEPT = Parkinson Research Examination of CEP-1347 Trial with a subsequent prospective study; ProPark = Profiling Parkinson's Disease study; Udall = Morris K. Udall Centers for Parkinson's Research. * Indicates Beta in a Cox model; ** indicates Beta in a logistic model at baseline; *** indicates Beta in a linear mixed model.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

Topics Discussed

Alert Me

Advertisement